C.F.R. homeSearch C.F.R.
C.F.R.Title 42Chapter IV—Centers for Medicare & Medicaid Services, Department of Health and Human ServicesSubchapter C—Medical Assistance ProgramsPart 447—Payments for ServicesSubpart I—Payment for Drugs

42 C.F.R. § 447.512 (2026)

Drugs: Aggregate upper limits of payment

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 12 IN 5Y cited 2009–2025 22citing cases
At a glance

Courts have cited this section in 22 opinions since 2009, 12 of them in the last five years.

(a) Multiple source drugs. Except for brand name drugs that are certified in accordance with paragraph (c) of this section, the agency payment for multiple source drugs must not exceed, in the aggregate, the amount that would result from the application of the specific limits established in accordance with § 447.514. If a specific limit has not been established under § 447.514, then the rule for “other drugs” set forth in paragraph (b) of this section applies.

(b) Other drugs. The agency payments for brand name drugs certified in accordance with paragraph (c) of this section and drugs other than multiple source drugs for which a specific limit has been established under § 447.514 must not exceed, in the aggregate, payment levels that the agency has determined by applying the lower of the following:

(1) AAC plus a professional dispensing fee established by the agency; or

(2) Providers' usual and customary charges to the general public.

(c) Certification of brand name drugs. (1) The upper limit for payment for multiple source drugs for which a specific limit has been established under § 447.514 does not apply if a physician certifies in his or her own handwriting (or by an electronic alternative means approved by the Secretary) that a specific brand is medically necessary for a particular beneficiary.

(2) The agency must decide what certification form and procedure are used.

(3) A check off box on a form is not acceptable but a notation like “brand necessary” is allowable.

(4) The agency may allow providers to keep the certification forms if the forms will be available for inspection by the agency or HHS.

The 20 cases that cite 42 C.F.R. § 447.512 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENAstrazeneca LP v. State, 41 So. 3d 15 (Ala. 2009).
cites § 447.512 8×cited by 15 cases
The case’s holding
A party cannot reasonably rely on published list prices as net prices where it had actual knowledge that the published prices excluded discounts, so fraud claims premised on that reliance fail.
Later courts cite it for
“the industry - and the ama in particular - was at all relevant times fully cognizant of the fact that the manufacturer's published drug prices were list prices, which excluded discounts.” · 2 citing courts
2
REDMichael Yarberry v. Supervalu Inc., 9 F.4th 455 (7th Cir. 2021).
cites § 447.512 4×cited by 17 cases
Vacated by the U.S. Supreme Court in this case: United States ex rel. Schutte v. Supervalu Inc. (2023).
Where it cites § 447.512
“” 1 42 C.F.R. § 447.512 (b). Because both Medicare and 1 While the state plans for the four states implicated in this appeal contain definitions of U&C price that have slight variances from the No.”
The case’s holding
A defendant lacks the requisite scienter under the False Claims Act if its interpretation of a regulation is objectively reasonable and lacks specific authoritative guidance.
Later courts cite it for
“authoritative guidance must have a high level of specificity to control an issue.” · 4 citing courts
cites § 447.512 1×cited by 69 cases
Where it cites § 447.512
“See 42 CFR § 447.512 (b)(2) (2021). Those regu- lations limit any reimbursement to the lower of two amounts, one of which is the healthcare provider's “usual and customary charges [for the drug] to the general public.”
The case’s holding
The False Claims Act scienter requirement refers to a defendant's subjective knowledge and beliefs rather than what an objectively reasonable person may have known or believed.
Later courts cite it for
“the fca's scienter element refers to respondents' knowledge and subjective beliefs-not to what an objectively reasonable person may have known or believed.” · 40 citing courts
4
GREENThomas Proctor v. Safeway, Inc., 30 F.4th 649 (7th Cir. 2022).
cites § 447.512 4×cited by 4 cases
Where it cites § 447.512
“” 42 C.F.R. § 447.512 (b). The regulation does not define “to the general public.”
Later courts cite it for
“put any of this in writing to stores because our official policy is we do not match.” · 2 citing courts
5
GREENUnited States ex rel. Garbe v. Kmart Corp., 824 F.3d 632 (7th Cir. 2016).
cites § 447.512 1×cited by 38 cases
Where it cites § 447.512
“1999) (interpreting 42 C.F.R. § 447.512 (b), then numbered 42 C.”
The case’s holding
Prices offered to the general public through discount programs constitute the usual and customary charges if those prices represent the lowest amounts for which the drugs are widely available.
Later courts cite it for
“because kmart offered the terms of its 'discount programs' to the general public and made them the lowest prices for which its drugs were widely and consistently available, the kmart 'discount' prices at issue represented the 'usual and customary charges for the drugs.” · 4 citing courts
cites § 447.512 4×cited by 8 cases
Where it cites § 447.512
“See 42 C.F.R. § 447.512 . The first FUL applies to “multiple source drugs” 1 that CMS has specifically listed, and it is based on the price of the least costly therapeutic equivalent drug.”
7
GREENSandoz, Inc. v. State, 100 So. 3d 514 (Ala. 2012).
cites § 447.512 3×cited by 11 cases
Where it cites § 447.512
“1 State’s brief, at 5 (citing 42 C.F.R. § 447.512 (2010) (formerly 42 C.”
Later courts cite it for
“the defendant's suppression induced the plaintiff to act or refrain from acting.” · 2 citing courts
8
GREENU.S. ex rel. Azam Rahimi v. Rite Aid Corp., 3 F.4th 813 (6th Cir. 2021).
cites § 447.512 1×cited by 16 cases
Where it cites § 447.512
“See 42 C.F.R. § 447.512 (b)(2). In general terms, this means that pharmacies cannot charge the government more than the “cash price” offered to the public to fill such prescriptions.”
The case’s holding
A public disclosure exists if multiple sources of information collectively reveal the allegation of fraud and its essential elements.
Later courts cite it for
“a public disclosure can also be piecemeal so long as the multiple sources of information reveal the allegation of fraud and its essential elements.” · 3 citing courts
9
GREENState v. Abbott Labs., 2012 WI 62, 816 N.W.2d 145.
cites § 447.512 1×cited by 23 cases
Where it cites § 447.512
“42 C.F.R. § 447.512 (b). The regulations define EAC as the "best estimate of the price generally and currently paid by providers for a drug.”
The case’s holding
Claims brought under the Deceptive Trade Practices Act carry a constitutional right to a jury trial because the statute is an essential counterpart to the common law claim of cheating.
Later courts cite it for
“that the defendant made a representation to the public with the intent to induce an obligation. . . .” · 1 citing court
cites § 447.512 1×cited by 18 cases
Where it cites § 447.512
“42 C.F.R. § 447.512 (b). 1 Federal Regulations defined EAC as Medicaid’s “best estimate of the price generally and currently paid by providers for a drug marketed or sold by a particular manufacturer or labeler in the package size of drugs most frequently purchased by providers.”
Later courts cite it for
“fraud is essentially a question of fact best left for the fact-finder.” · 2 citing courts
cites § 447.512 1×cited by 39 cases
Where it cites § 447.512
“See 42 CFR §447.512 (b)(2) (2021). Those regulations limit any reimbursement to the lower of two amounts, one of which is the healthcare provider’s “usual and customary charges [for the drug] to the general public.”
12
GREENUnited States v. SuperValu, Inc., 218 F. Supp. 3d 767 (C.D. Ill. 2016).
cites § 447.512 1×cited by 4 cases
Where it cites § 447.512
“” 42 C.F.R. § 447.512 (b). The State Medicaid usual and customary regulations are based on this requirement and all State plans must periodically determine that they “are in accordance with § 447.”
13
GREENUnited States ex rel. Winkelman v. CVS Caremark Corp., 118 F. Supp. 3d 412 (D. Mass. 2015).
cites § 447.512 1×cited by 2 cases
Where it cites § 447.512
“¶ 20b (emphasis in original) (citing 42 C.F.R. § 447.512 (b)). As a result, the state Medicaid programs of the Plaintiff-states require that pharmacies submit their usual and customary prices and will reimburse the lesser of the, various measures.”
14
NO FLAGLouisiana Dep't of Health v. HHS, No. 20-60213 (5th Cir. Apr. 5, 2021).
cites § 447.512 5×cited by 0 casesunpublished
Summary
No passage or summary on file for this case yet.
15
GREENIA Dept. of Human Servs. v. Centers for Medicare, No. 08-3284 (8th Cir. Aug. 19, 2009).
cites § 447.512 4×cited by 0 cases
Where it cites § 447.512
“See 42 C.F.R. § 447.512 . The first FUL applies to “multiple source drugs”1 that CMS has specifically listed, and it is based on the price of the least costly therapeutic equivalent drug.”
16
NO FLAGRonald Streck v. Eli Lilly & Co., No. 24-1884 (7th Cir. Sept. 11, 2025).
cites § 447.512 2×cited by 0 cases
Where it cites § 447.512
“42 C.F.R. §447.512 (b). So, the federal govern- ment’s obligation turns on the amount end-users (pharmacies or customers) paid for the drug.”
17
NO FLAGRonald Streck v. Eli Lilly & Co., No. 24-1352 (7th Cir. Sept. 11, 2025).
cites § 447.512 2×cited by 0 cases
Where it cites § 447.512
“42 C.F.R. §447.512 (b). So, the federal govern- ment’s obligation turns on the amount end-users (pharmacies or customers) paid for the drug.”
18
NO FLAGRonald Streck v. Eli Lilly & Co., No. 23-3035 (7th Cir. Sept. 11, 2025).
cites § 447.512 2×cited by 0 cases
Where it cites § 447.512
“42 C.F.R. §447.512 (b). So, the federal govern- ment’s obligation turns on the amount end-users (pharmacies or customers) paid for the drug.”
19
NO FLAGRonald J. Streck v. Eli Lilly & Co., No. 23-2958 (7th Cir. Sept. 11, 2025).
cites § 447.512 2×cited by 0 cases
Where it cites § 447.512
“42 C.F.R. §447.512 (b). So, the federal govern- ment’s obligation turns on the amount end-users (pharmacies or customers) paid for the drug.”
20
NO FLAGRonald J. Streck v. Eli Lilly & Co., No. 23-2216 (7th Cir. Sept. 11, 2025).
cites § 447.512 2×cited by 0 cases
Where it cites § 447.512
“42 C.F.R. §447.512 (b). So, the federal govern- ment’s obligation turns on the amount end-users (pharmacies or customers) paid for the drug.”

Show all 22 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200920172025

One bar per year. Tallest: 6 cases in 2025. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
7th Cir.9Ala.28th Cir.2C.D. Ill.2SCOTUS25th Cir.16th Cir.1D. Mass.1

The 8 courts with the most citing cases, of 10 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 22 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com